TScan Therapeutics $140.6 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Davis Polk advised the joint book-running managers in connection with a $140.6 million SEC-registered common stock and pre-funded warrants offering by TScan Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “TCRX.”
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T-cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
The Davis Polk corporate team included partner Marcel Fausten and associates Robert MacKenzie and Jenny Li. The tax team included partner Kara L. Mungovan and associate Dov Sussman. The intellectual property team included partner David R. Bauer and associates S. Dream Montgomery and Shreya R. Kundur. All members of the Davis Polk team are based in the New York office.